Erratum: Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-Medicare analysis (Cancer DOI: 10.1002/cncr.28372);Improved survival using intensity-modulated radiation therapy in head and neck cancers: A SEER-medicare analysis

Cancer

Volumn 120, Issue 5, 2014, Pages 702-710

  Beadle, Beth M ^a   Liao, Kai Ping ^a   Elting, Linda S ^a   Buchholz, Thomas A ^a   Ang, K Kian ^a   Garden, Adam S ^a   Guadagnolo, B Ashleigh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

head and neck cancer; intensity modulated radiation therapy; oropharynx cancer; radiation oncology; SEER Medicare

Indexed keywords

AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY;

HEAD AND NECK CANCER; INTENSITY-MODULATED RADIATION THERAPY; OROPHARYNX CANCER; RADIATION ONCOLOGY; SEER-MEDICARE;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICARE; PROPENSITY SCORE; RADIOTHERAPY, INTENSITY-MODULATED; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84896702689     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28633     Document Type: Erratum

References (34)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck. 2004;26: 796-807.
3. Chambers MS, Rosenthal DI, Weber RS. Radiation-induced xerostomia. Head Neck. 2007;29:58-63.
4. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695-704.
5. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001;23:389-398.
6. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770-3776.
7. Guadagnolo BA, Liu CC, Cormier JN, Du XL. Evaluation of trends in the use of intensity-modulated radiotherapy for head and neck cancer from 2000 through 2005: socioeconomic disparity and geographic variation in a large population-based cohort. Cancer. 2010; 116:3505-3512.
8. Sher DJ, Neville BA, Chen AB, Schrag D. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis. Int J Radiat Oncol Biol Phys. 2011;81:e197-e206.
9. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981-991.
10. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25: 4873-4879.
11. Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1309-1317.
12. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? Cancer Treat Rev. 2011;37:511-519.
13. Nutting CM, Morden JP, Harrington KJ, et al; PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12:127-136.
14. Gupta T, Agarwal J, Jain S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol. 2012;104:343-348.
15. Eisbruch A, Harris J, Garden AS, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22). Int J Radiat Oncol Biol Phys. 2010;76:1333-1338.
16. Lee IJ, Koom WS, Lee CG, et al. Risk factors and dose-effect relationship for mandibular osteoradionecrosis in oral and oropharyn-geal cancer patients. Int J Radiat Oncol Biol Phys. 2009;75:1084-1091.
17. Yu JB, Soulos PR, Sharma R, et al. Patterns of care and outcomes associated with intensity-modulated radiation therapy versus conventional radiation therapy for older patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:e101-e107.
18. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2008). 2011.
19. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
20. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and gen-eralizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
21. Hu CY, Xing Y, Cormier JN, Chang GJ. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival. Cancer. 2013;119:1900-1907.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
23. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care. 2006;44:921-928.
24. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584-590.
25. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
26. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51:171-184.
27. Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ. 2008;27:531-543.
28. Terza JV, Bradford WD, Dismuke CE. The use of linear instrumental variables methods in health services research and health economics: a cautionary note. Health Serv Res. 2008;43:1102-1120.
29. Garden AS, Morrison WH, Wong PF, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007;67:438-444.
30. Daly ME, Le QT, Maxim PG, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010;76:1339-1346.
31. Lok BH, Setton J, Caria N, et al. Intensity-modulated radiation therapy in oropharyngeal carcinoma: effect of tumor volume on clinical outcomes. Int J Radiat Oncol Biol Phys. 2012;82:1851-1857.
32. Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL. Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst. 2010;102:1780-1793.
33. Tan HJ, Norton EC, Ye Z, Hafez KS, Gore JL, Miller DC. Longterm survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA. 2012;307:1629-1635.
34. Yong JH, Beca J, O'Sullivan B, et al. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer. Clin Oncol (R Coll Radiol). 2012;24:532-538.